Thumbnail
Access Restriction
Open

Author Kasamatsu, Atsushi ♦ Uzawa, Katsuhiro ♦ Minakawa, Yasuyuki ♦ Ishige, Shunsaku ♦ Kasama, Hiroki ♦ Endo-Sakamoto, Yosuke ♦ Ogawara, Katsunori ♦ Shiiba, Masashi ♦ Takiguchi, Yuichi ♦ Tanzawa, Hideki
Source United States Department of Energy Office of Scientific and Technical Information
Content type Text
Language English
Subject Keyword APPLIED LIFE SCIENCES ♦ ANGIOGENESIS ♦ APOPTOSIS ♦ BIOLOGICAL MARKERS ♦ BIOPSY ♦ CARCINOMAS ♦ CELL PROLIFERATION ♦ CHEMOTHERAPY ♦ COMPARATIVE EVALUATIONS ♦ IN VITRO ♦ IN VIVO ♦ LEUCINE ♦ METASTASES ♦ MICE ♦ PATIENTS ♦ PLANT GROWTH ♦ SIGNALS ♦ URACILS
Abstract Highlights: • DCN is significantly up-regulated in chemoresistant cancer cell lines. • DCN is a key regulator for chemoresistant mechanisms in vitro and in vivo. • DCN predicts the clinical responses to S-1 NAC for patients with oral cancer. - Abstract: We reported previously that decorin (DCN) is significantly up-regulated in chemoresistant cancer cell lines. DCN is a small leucine-rich proteoglycan that exists and functions in stromal and epithelial cells. Accumulating evidence suggests that DCN affects the biology of several types of cancer by directly/indirectly targeting the signaling molecules involved in cell growth, survival, metastasis, and angiogenesis, however, the molecular mechanisms of DCN in chemoresistance and its clinical relevance are still unknown. Here we assumed that DCN silencing cells increase chemosusceptibility to S-1, consisted of tegafur, prodrug of 5-fluorouracil. We first established DCN knockdown transfectants derived from oral cancer cells for following experiments including chemosusceptibility assay to S-1. In addition to the in vitro data, DCN knockdown zenografting tumors in nude mice demonstrate decreasing cell proliferation and increasing apoptosis with dephosphorylation of AKT after S-1 chemotherapy. We also investigated whether DCN expression predicts the clinical responses of neoadjuvant chemotherapy (NAC) using S-1 (S-1 NAC) for oral cancer patients. Immunohistochemistry data in the preoperative biopsy samples was analyzed to determine the cut-off point for status of DCN expression by receiver operating curve analysis. Interestingly, low DCN expression was observed in five (83%) of six cases with complete responses to S-1 NAC, and in one (10%) case of 10 cases with stable/progressive disease, indicating that S-1 chemosensitivity is dramatically effective in oral cancer patients with low DCN expression compared with high DCN expression. Our findings suggest that DCN is a key regulator for chemoresistant mechanisms, and is a predictive immunomarker of the response to S-1 NAC and patient prognosis.
ISSN 0006291X
Educational Use Research
Learning Resource Type Article
Publisher Date 2015-01-30
Publisher Place United States
Journal Biochemical and Biophysical Research Communications
Volume Number 457
Issue Number 1


Open content in new tab

   Open content in new tab